CAR-NK for tumor immunotherapy: Clinical transformation and future prospects
Wenxiu Wang, Jingting Jiang, Changping Wu, Wenxiu Wang, Jingting Jiang, Changping Wu
Abstract
Recently, the use of chimeric antigen receptor-modified T (CAR-T)-cells in the treatment of hematological tumors has been successful and has become a clinical hotspot in tumor immunotherapy. However, their wide application is limited by inherent risks such as graft-versus-host disease (GvHD) and the amount of time it takes to produce CAR-T cells. Natural killer (NK) cells can be xenografted and have the potential to become off-the-shelf products, making CAR-NK cell therapies universal products. These products may be safer than CAR-T cell therapy. Considering that the fundamental researche is still in its infancy, this review focuses on clinical achievements and new strategies for improving the safety and efficacy of CAR-NK cell therapy, as well as the corresponding challenges.
Keywords: Chimeric antigen receptor; Genetic engineering; NK-92; Natural killer cells.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.
Source: PubMed